Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh(Cedars-Sinai Medical Center), James Carmichael(AstraZeneca (United Kingdom)), Richard T. Penson(Dana-Farber Cancer Institute), Michael Friedländer(Prince of Wales Hospital), Bethan Powell(University of California, San Francisco), Katherine M. Bell‐McGuinn(Memorial Sloan Kettering Cancer Center), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), Jeffrey N. Weitzel(City of Hope), Ana Oaknin(Vall d'Hebron Hospital Universitari), Niklas Loman(Skåne University Hospital), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Rita K. Schmutzler(University of Cologne), Ursula A. Matulonis(Massachusetts General Hospital), Mark Wickens(AstraZeneca (United Kingdom)), Andrew Tutt(Breast Cancer Now)
Cited by 2,283
Abstract
Related Papers
No related papers found
Powered by citation graph analysis